Sensitivity Analysis: Assessment of Relationship Between Metformin and Clinical Outcomes By Diabetes Status and Primary Treatment of Prostate Cancer

	pHR	95% CI	P-Value	I2	# Studies	Name of Studies
Men with Diabetes and Prostate Cancer
BCR	0.93	0.61-1.42	0.74	NA	1	Allott 2013
CRPC¥	2.98	0.98-9.05	0.054	NA	1	Allott 2013
Metastases¥	2.53	0.70-9.22	0.158	NA	1	Allott 2013
All-cause mortality	0.95	0.91-0.99	0.02	65%	4	He 2011, Currie 2012, Margel 2013, Bensimon 2014
Pca-Specific mortality	0.81	0.75-0.87	<0.0001	0%	2	Margel 2013, Bansimon 2014
Men with Prostate Cancer with and without diabetes
BCR	0.80	0.62-1.03	0.08	40%	4	Patel 2010, Rieken 2013, Spratt 2013, Kaushik 2014
CRPC€	0.07	0.0009-0.55	<0.01	NA	1	Spratt 2013
Metastases	0.84	0.58-1.22	0.30	0%	2	Rieken 2013, Kaushik 2014
All-cause mortality	0.73	0.52-1.03	0.07	87%	2	Sparatt 2013; Kaushik 2014
Pca-Specific mortality	0.52	0.07-3.72	0.51	83%	2	Sparatt 2013; Kaushik 2014
Men Treated with Radical Prostatectomy
BCR	0.89	0.73-1.10	0.29	0%	4	Patel 2010; Allott 2013; Rieken 2013; Kaushik 2014
CRPC¥	2.98	0.98-9.05	0.054	NA	1	Allott 2013
Metastases	0.84	0.58-1.22	0.30	0%	2	Rieken 2013, Kaushik 2014
All-cause mortality	1.17	0.73-7.86	0.52	NA	1	Kaushik 2014
Pca-Specific mortality	1.42	0.44-4.58	0.56	NA	1	Kaushik 2014
Men Treated with External-beam Radiation Therapy
BCR	0.5	0.31-0.80	0.004	NA	1	Spratt 2013
CRPC€	0.068	0.0009-0.55	<0.01	NA	1	Spratt 2013
Metastases	0.27	0.13-0.56	<0.01	NA	1	Spratt 2013
All-cause mortality	0.44	0.27-0.72	0.001	NA	1	Spratt 2013
Pca-Specific mortality	0.19	0.19-0.60	0.005	NA	1	Spratt 2013

Note:

^¥Spratt 2014 reported adjusted odd ratio for CRPC;

^€Allott 2013 reported unadjusted hazard ratio for CRPC and metastases.